Spots Global Cancer Trial Database for Standard Chemotherapy With Blueberry Powder in Non-Small Cell Lung Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Standard Chemotherapy With Blueberry Powder in Non-Small Cell Lung Cancer

Official Title: Salvage Therapy With Docetaxel and Blueberry Powder in Non-Small Cell Lung Cancer

Study ID: NCT01426620

Conditions

Non-small Cell Lung Cancer

Interventions

Blueberry powder

Study Description

Brief Summary: This phase II trial will evaluate phyto-therapy's, in the form of blueberry powder, synergistic effect on second-line therapy for non-small cell lung cancer (NSCLC). The proposition is that the addition of blueberry polyphenolics to routine docetaxel therapy will have a significant, positive effect in the response rate and overall survival.

Detailed Description: This study is designed to evaluate the feasibility of using blueberry powder (rich in anthocyanidins) as an adjunct therapy with the conventional chemotherapy drug paclitaxel/docetaxel for treatment of NSCLC. The study is based on information from published studies in which blueberry anthocyanidins (bioflavonoids which give blueberries their color) have been shown to regulate a vast array of molecular targets, and on our own exciting and compelling preliminary data showing that blueberry anthocyanidins elicited potent synergistic chemo-sensitizing effects in two highly aggressive non-small cell lung cancer (NSCLC) cell lines.